LT3 Stock Overview Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add notePrice History & Performance
Summary of share price highs, lows and changes for Axogen Historical stock prices Current Share Price US$14.20 52 Week High US$14.30 52 Week Low US$5.10 Beta 1.06 1 Month Change 14.52% 3 Month Change 13.60% 1 Year Change 123.62% 3 Year Change 63.22% 5 Year Change -12.35% Change since IPO 84.08%
Recent News & Updates
New minor risk - Shareholder dilution Nov 09
Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.095 loss in 3Q 2023) Nov 09
Axogen, Inc. Maintains Earnings Guidance for 2024 Nov 08
No longer forecast to breakeven Nov 07
Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Forecast to breakeven in 2025 Oct 15 See more updates
New minor risk - Shareholder dilution Nov 09
Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.095 loss in 3Q 2023) Nov 09
Axogen, Inc. Maintains Earnings Guidance for 2024 Nov 08
No longer forecast to breakeven Nov 07
Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Forecast to breakeven in 2025 Oct 15 Axogen, Inc. Announces Chief Executive Officer Changes
New major risk - Share price stability Aug 09
Second quarter 2024 earnings released: US$0.044 loss per share (vs US$0.15 loss in 2Q 2023) Aug 09
AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024 Aug 08
AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 23
Forecast breakeven date pushed back to 2026 Jul 02
Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix Jun 24
Forecast breakeven date moved forward to 2025 Jun 16
Forecast breakeven date moved forward to 2025 May 31
Axogen, Inc. Provides Revenue Guidance for the Year 2024 May 03
First quarter 2024 earnings released: US$0.15 loss per share (vs US$0.17 loss in 1Q 2023) May 02
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix Apr 30
AxoGen, Inc., Annual General Meeting, Jun 05, 2024 Apr 26
AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 17
New minor risk - Shareholder dilution Mar 30
Vice President of Operations recently sold €293k worth of stock Mar 10
AxoGen, Inc. Announces Executive Changes Mar 10
New minor risk - Shareholder dilution Mar 06
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Mar 06
Full year 2023 earnings released: US$0.51 loss per share (vs US$0.69 loss in FY 2022) Mar 05
Forecast breakeven date pushed back to 2026 Mar 05
Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study Jan 19 Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors Dec 27
Insider recently sold €87k worth of stock Dec 14
AxoGen, Inc. Announces CFO Changes Dec 06
Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022) Nov 09
Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023 Nov 08
AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 19
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector Sep 06
Independent Director recently bought €56k worth of stock Aug 20
New minor risk - Share price stability Aug 10
Axogen, Inc. Provides Revenue Guidance for the Year 2023 Aug 09
Forecast to breakeven in 2025 Aug 08 AxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023
Director recently sold €341k worth of stock Jun 07
Director recently sold €64k worth of stock May 25
AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023 May 10
First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.27 loss in 1Q 2022) May 10
No longer forecast to breakeven Mar 28
No longer forecast to breakeven Mar 16
Full year 2022 earnings released: US$0.69 loss per share (vs US$0.66 loss in FY 2021) Mar 15
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer Feb 14 AxoGen, Inc. to Report Q4, 2022 Results on Mar 14, 2023
Forecast to breakeven in 2025 Dec 31
Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.17 loss in 3Q 2021) Nov 09
AxoGen, Inc. Updates Earnings Guidance for the Full Year 2022 Nov 09
Axogen, Inc. Announces Directorate Changes Nov 01
AxoGen, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 21
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.19 loss in 2Q 2021) Aug 04 Eric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, Inc
Axogen, Inc. Appoints William Burke to Board of Directors Jul 12
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 1Q 2021) May 06 AxoGen, Inc. Provides Earnings Guidance for the Full Year of 2022
AxoGen, Inc., Annual General Meeting, May 25, 2022 Apr 15
AxoGen, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 14
AxoGen, Inc. Announces Board Changes Apr 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
AxoGen, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021 Jan 12
Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.037 loss in 3Q 2020) Nov 05
Axogen RECON(SM) Clinical Study Completes Subject Follow-up Sep 02
Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2020) Aug 06
First quarter 2021 earnings released: US$0.16 loss per share (vs US$0.21 loss in 1Q 2020) May 07
AxoGen, Inc. Re-Iterates Revenue Guidance for the Full Year of Fiscal 2021 May 06 Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President
New 90-day high: €17.50 Feb 24
Full year 2020 earnings released: US$0.59 loss per share (vs US$0.74 loss in FY 2019) Feb 24
Revenue beats expectations Feb 24
Axogen, Inc. Announces Completion of Pilot Phase Analysis for Its Repose Clinical Study Feb 19
AxoGen, Inc. to Report Q4, 2020 Results on Feb 22, 2021 Jan 12
AxoGen, Inc Promotes Dr. Angelo Scopelianos' as Chief Research and Development Officer Jan 08
New 90-day high: €15.30 Jan 08
Chairman recently sold €51k worth of stock Jan 01
New 90-day high: €14.50 Dec 24
New 90-day high: €13.10 Dec 05
New 90-day high: €12.40 Nov 12
Revenue beats expectations Nov 05
Third quarter 2020 earnings released: US$0.037 loss per share Nov 05 Shareholder Returns LT3 DE Medical Equipment DE Market 7D 4.4% -2.9% -2.6% 1Y 123.6% -8.5% 6.9%
See full shareholder returns
Return vs Market: LT3 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is LT3's price volatile compared to industry and market? LT3 volatility LT3 Average Weekly Movement 8.3% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LT3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LT3's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
Show more Axogen, Inc. Fundamentals Summary How do Axogen's earnings and revenue compare to its market cap? LT3 fundamental statistics Market cap €659.66m Earnings (TTM ) -€13.71m Revenue (TTM ) €173.33m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LT3 income statement (TTM ) Revenue US$180.86m Cost of Revenue US$38.43m Gross Profit US$142.43m Other Expenses US$156.74m Earnings -US$14.31m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.33 Gross Margin 78.75% Net Profit Margin -7.91% Debt/Equity Ratio 50.0%
How did LT3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 01:33 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Axogen, Inc. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Gorman BTIG William Plovanic Canaccord Genuity Caitlin Cronin Canaccord Genuity
Show 15 more analysts